Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 22442059.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0626.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops. As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors.
Medical subject headings
- Azabicyclo Compounds
- Drug Resistance, Neoplasm
- HSP90 Heat-Shock Proteins
- Melanoma
- Phthalic Acids
- Proto-Oncogene Proteins B-raf
- Signal Transduction